Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.

[1]  T. Bekaii-Saab,et al.  Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  B. Comte,et al.  An onco-geriatric approach to select older patients for optimal treatments of pancreatic adenocarcinoma. , 2018, Journal of geriatric oncology.

[3]  V. Lemmens,et al.  Patient characteristics and treatment considerations in pancreatic cancer: a population based study in the Netherlands , 2018, Acta oncologica.

[4]  J. Jónasson,et al.  Incidence, diagnostic, treatment and outcome of patients diagnosed with cancer of the pancreas during 1986–2009: a population-based study , 2018, Scandinavian journal of gastroenterology.

[5]  J. Raoul,et al.  How to treat pancreatic adenocarcinoma in elderly: How far can we go in 2017? , 2017, Journal of geriatric oncology.

[6]  G. Prager,et al.  Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer , 2017, memo - Magazine of European Medical Oncology.

[7]  M. Abu Hilal,et al.  Elderly patients have similar short term outcomes and five-year survival compared to younger patients after pancreaticoduodenectomy. , 2017, International journal of surgery.

[8]  T. Conroy,et al.  Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions , 2017, Therapeutic advances in gastroenterology.

[9]  E. Kipps,et al.  Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy , 2017, Therapeutic advances in medical oncology.

[10]  V. Lemmens,et al.  Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer , 2017, Cancer medicine.

[11]  O. Bouché,et al.  Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis. , 2017, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[12]  I. Ilic,et al.  Epidemiology of pancreatic cancer , 2016, World journal of gastroenterology.

[13]  V. Lemmens,et al.  Pancreatic cancer surgery in elderly patients: Balancing between short-term harm and long-term benefit. A population-based study in the Netherlands , 2016, Acta oncologica.

[14]  Yan-Shen Shan,et al.  Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial , 2016, The Lancet.

[15]  T. Conroy,et al.  Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  A. Carrato,et al.  A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs , 2015, Journal of Gastrointestinal Cancer.

[17]  G. Wakabayashi,et al.  Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer , 2015, British Journal of Cancer.

[18]  T. Strom,et al.  Resected pancreatic cancer outcomes in the elderly. , 2015, Journal of geriatric oncology.

[19]  U. Nielsen,et al.  Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. , 2014, Cancer research.

[20]  Hongliu Sun,et al.  Survival improvement in patients with pancreatic cancer by decade: A period analysis of the SEER database, 1981–2010 , 2014, Scientific Reports.

[21]  B. Dörken,et al.  Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[23]  M. Moore,et al.  PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT). , 2014 .

[24]  F. Dominici,et al.  National trends in pancreatic cancer outcomes and pattern of care among Medicare beneficiaries, 2000 through 2010 , 2014, Cancer.

[25]  Todd Gress,et al.  Pancreatic Cancer Survival in Elderly Patients Treated With Chemotherapy , 2014, Pancreas.

[26]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[27]  Seung June Lee,et al.  5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy , 2013, Chemotherapy.

[28]  F. J. Ramos,et al.  A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[30]  John W. Park,et al.  Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. , 2006, Cancer research.

[31]  W. Morton.  The elderly patient. , 1953, Physiotherapy.